Disclosure Panels Details Page
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel - Disclosures as of 04/11/2023
|
Panel Member
(Spouse/Domestic Partner/Dependent) |
Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Employment/ Governing Board, Patent, Equity, or Royalty | Has Attended |
|---|---|---|---|---|---|
| Zahraa AlHilli MD | None | None | None | None | ✔ |
| Banu Arun MD | AstraZeneca Pharmaceuticals LP | None | None | None | ✔ |
| Marian Birkeland PhD | None | None | None | None | - |
| Nicole Blankenhorn | None | None | None | None | ✔ |
| Saundra Buys MD | None | None | None | None | - |
| Heather Cheng MD, PhD | Clovis Oncology Color Health, Inc Janssen Pharmaceutica Products, LP Promontory Therapeutics (formerly Phosplatin) |
None | None | UpToDate | - |
| Jane Churpek MD, MS | Department of Defense NIH |
MDS Foundation RUNX1 Research Program |
UpToDate,Inc | MDS Foundation|RUNX1 Research Program | - |
| Mary Daly MD, PhD, FACP | None | None | None | None | ✔ |
| Susan Darlow PhD | None | None | None | None | ✔ |
| Susan Domchek MD | None | None | None | None | - |
| Mary Dwyer MS | None | None | None | None | ✔ |
| Ahmed Elkhanany MD | None | AstraZeneca Pharmaceuticals LP | None | None | ✔ |
| Susan Friedman DVM | None | None | None | None | ✔ |
| Veda Giri MD | None | None | None | None | - |
| Michael Goggins MD | None | None | None | None | - |
| Kristina Gregory MSN, RN | None | None | None | None | ✔ |
| Andrea Hagemann MD, MSCI | None | None | None | None | ✔ |
| Ashley Hendrix MD, MBA | None | None | None | None | ✔ |
| Erin Hesler | None | None | None | None | - |
| Mollie Hutton MS, CGC | None | None | None | None | - |
| Robin Isaac PharmD | None | None | None | None | ✔ |
| Beth Karlan MD | GRAIL | BioRad Bluestar Genomics Global Coalition for Adaptive Research Mercy BioAnalytics Natera Ovarian Cancer Research Alliance |
None | None | ✔ |
| Nawal Kassem MD, MS | None | None | None | None | ✔ |
| Seema Khan MD | None | Besins Healthcare Ireland Ltd. | None | None | ✔ |
| Wendy Kohlmann MS, CGC | None | None | None | None | ✔ |
| Allison Kurian MD, MSc | Ambry Genetics Myriad Genetic Laboratories, Inc. |
None | None | None | ✔ |
| Christine Laronga MD, FACS | None | None | None | Royalties for editorial work | ✔ |
| Julie Mak MS, MSc, CGC | None | None | VSee | VSee | ✔ |
| John Mansour MD | None | None | None | None | ✔ |
| Kara Maxwell MD, PhD | None | None | None | None | ✔ |
| Kevin McDonnell MD, PhD | None | None | None | None | ✔ |
| Carolyn Menendez MD | None | None | None | None | ✔ |
| Sofia Merajver MD, PhD | None | None | None | Founder and equity interest in InheRET, Inc. I do not believe that any change in the guidelines would benefit or harm the commercial potential of InheRET, Inc. | - |
| Barbara Norquist MD | None | None | None | None | - |
| Kenneth Offit MD, MPH | AnaNeo Therapeutics | None | None | None | ✔ |
| Tuya Pal MD | None | Natera | None | None | ✔ |
| Donna Powell DHSc, CMD, RT(T) | None | None | None | None | - |
| Dominique Rash MD | None | None | Varian Medical Systems, Inc. VisionRT |
None | ✔ |
| Gwen Reiser MS, CGC | None | None | None | None | ✔ |
| Leigha Senter-Jamieson MS, CGC | None | AstraZeneca Pharmaceuticals LP | AstraZeneca Pharmaceuticals LP GSK |
None | ✔ |
| Kristen Shannon MS, CGC | None | Expert Witness | None | None | ✔ |
| Kala Visvanathan MD, MHS | Cepheid Optra Health |
None | None | None | - |
| Jeanna Welborn MD | None | None | None | None | - |
| Myra Wick MD, PhD | Natera | American board of Medical Genetics and Genomics (ABMGG) | None | None | ✔ |
| Marie Wood MD | None | None | None | None | ✔ |
| Matthew Yurgelun MD | Janssen Pharmaceutica Products, LP | UpToDate | None | Facing Our Risk of Cancer Empowered (FORCE) advocacy group | - |